Developing country applications of Molecular farming: Case studies in South Africa and Argentina

Current Pharmaceutical Design

Volumn 19, Issue 31, 2013, Pages 5612-5621

  Rybicki, Edward P ^a   Hitzeroth, Inga I ^a   Meyers, Ann ^a   Dus Santos, Maria Jose ^b   Wigdorovitz, Andres ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

Author keywords

Beak and feather disease; Biofarming; Foot and mouth disease; Nanoantibody; Newcastle disease; Papillomavirus; Plant production; Policy; Rotavirus; Therapeutics; Vaccines

Indexed keywords

VACCINE;

AFRICA; ARGENTINA; BEAK AND FEATHER DISEASE; BLUETONGUE ORBIVIRUS; BOVINE VIRAL DIARRHEA; CIRCOVIRUS; COW; DEVELOPING COUNTRY; FOOD AND DRUG ADMINISTRATION; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; HUMAN; LAGOVIRUS; LIVESTOCK; MOLECULAR BIOLOGY; MOLECULAR FARMING; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PLANT DEVELOPMENT; PRIORITY JOURNAL; PSITTACINE; REVIEW; ROTAVIRUS; SOUTH AFRICA; WART VIRUS;

ANIMAL DISEASES; ANIMALS; ARGENTINA; CATTLE; DEVELOPING COUNTRIES; HUMANS; MOLECULAR FARMING; PLANTS, GENETICALLY MODIFIED; RABBITS; RECOMBINANT PROTEINS; SOUTH AFRICA; VACCINES; VETERINARY DRUGS;

EID: 84874073920     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319310015     Document Type: Review

References (53)

1. Fooks AR. Development of oral vaccines for human use. Current opinion in molecular therapeutics 2(1), 80-86 (2000).
2. Koprowski H, Yusibov V. The green revolution: plants as heterologous expression vectors. Vaccine 19(17-19), 2735-2741 (2001).
3. Walmsley AM, Arntzen CJ. Plants for delivery of edible vaccines. Current opinion in biotechnology 11(2), 126-129 (2000).
4. Yu J, Langridge WH. Novel Approaches to Oral Vaccines: Delivery of Antigens by Edible Plants. Current infectious disease reports 2(1), 73-77 (2000).
5. Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discovery Today 14(1-2), 16-24 (2009).
6. Fda FaDA. FDA approves new orphan drug to treat a form of Gaucher disease. (2012).
7. Rybicki EP. Third International Conference on Plant-Based Vaccines and Antibodies. Expert review of vaccines 8(9), 1151-1155 (2009).
8. Rybicki EP, Chikwamba R, Koch M, Rhodes JI, Groenewald JH. Plant-made therapeutics: an emerging platform in South Africa. Biotechnology advances 30(2), 449-459 (2012).
9. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnology Journal 8(5), 620-637 (2010).
10. Penney CA, Thomas DR, Deen SS, Walmsley AM. Plant-made vaccines in support of the Millennium Development Goals. Plant cell reports 30(5), 789-798 (2011).
11. Pérez Aguirreburualde MS, Gómez, M.C., Ostachuk, A., Wolman, F., Albanesi, G., Pecora, A., Odeon, A., Escribano, J.A., Ardila, F., Dus Santos, M.J., Wigdorovitz, A. Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants. Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants (2012).
12. Lentz EM, Mozgovoj MV, Bellido D, Dus Santos MJ, Wigdorovitz A, Bravo-Almonacid FF. VP8* antigen produced in tobacco transplastomic plants confers protection against bovine rotavirus infection in a suckling mouse model. Journal of biotechnology 156(2), 100-107 (2011).
13. Rybicki EP, Martin DP. Virus-Derived ssDNA Vectors for the Expression of Foreign Proteins in Plants. Current topics in microbiology and immunology (In Press) (2013).
14. Werner S, Breus O, Symonenko Y, Marillonnet S, Gleba Y. Highlevel recombinant protein expression in transgenic plants by using a double-inducible viral vector. Proceedings of the National Academy of Sciences of the United States of America 108(34), 14061-14066 (2011).
15. Carrillo C, Wigdorovitz A, Oliveros JC et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. Journal of virology 72(2), 1688-1690 (1998).
16. Carrillo C, Wigdorovitz A, Trono K et al. Induction of a virusspecific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants. Viral immunology 14(1), 49-57 (2001).
17. Wigdorovitz A, Perez Filgueira DM, Robertson N et al. Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1. Virology 264(1), 85-91 (1999).
18. Saiz JC, Cairo J, Medina M et al. Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization. Journal of virology 68(7), 4557-4564 (1994).
19. Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263(2), 496-506 (1999).
20. Dus Santos MJ, Carrillo C, Ardila F et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen. Vaccine 23(15), 1838-1843 (2005).
21. Dus Santos MJ, Wigdorovitz A, Trono K et al. A novel methodology to develop a foot and mouth disease virus (FMDV) peptidebased vaccine in transgenic plants. Vaccine 20(7-8), 1141-1147 (2002).
22. Wigdorovitz A, Mozgovoj M, Santos MJ et al. Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants. The Journal of general virology 85(Pt 7), 1825-1832 (2004).
23. Perez Filgueira DM, Mozgovoj M, Wigdorovitz A et al. Passive protection to bovine rotavirus (BRV) infection induced by a BRV VP8* produced in plants using a TMV-based vector. Archives of virology 149(12), 2337-2348 (2004).
24. Perez Filgueira DM, Zamorano PI, Dominguez MG et al. Bovine herpes virus gD protein produced in plants using a recombinant tobacco mosaic virus (TMV) vector possesses authentic antigenicity. Vaccine 21(27-30), 4201-4209 (2003).
25. Pérez Aguirreburualde MS, Gomez MC, Ostachuk A et al. Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants. Veterinary immunology and immunopathology 151(3-4), 315-324 (2013).
26. Wirth S, Segretin ME, Mentaberry A, Bravo-Almonacid F. Accumulation of hEGF and hEGF-fusion proteins in chloroplasttransformed tobacco plants is higher in the dark than in the light. Journal of biotechnology 125(2), 159-172 (2006).
27. Lentz EM, Segretin ME, Morgenfeld MM et al. High expression level of a foot and mouth disease virus epitope in tobacco transplastomic plants. Planta 231(2), 387-395 (2010).
28. Lentz EM, Garaicoechea L, Alfano EF, Parreno V, Wigdorovitz A, Bravo-Almonacid FF. Translational fusion and redirection to thylakoid lumen as strategies to improve the accumulation of a camelid antibody fragment in transplastomic tobacco. Planta 236(2), 703-714 (2012).
29. Coceres VM, Becher ML, De Napoli MG, Corvi MM, Clemente M, Angel SO. Evaluation of the antigenic value of recombinant Toxoplasma gondii HSP20 to detect specific immunoglobulin G antibodies in Toxoplasma infected humans. Experimental parasitology 126(2), 263-266 (2010).
30. Laguia-Becher M, Martin V, Kraemer M et al. Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. BMC Biotechnol 10, 52 (2010).
31. Corigliano MG, Maglioco A, Laguia B.M et al. Plant Hsp90 proteins interact with B-cells and stimulate their proliferation. PLoS One 6(6), e21231 (2011).
32. Zelada AM, Calamante G, De La Paz Santangelo M et al. Expression of tuberculosis antigen ESAT-6 in Nicotiana tabacum using a potato virus X-based vector. Tuberculosis 86(3-4), 263-267 (2006).
33. Nelson G, Marconi P, Periolo O, La Torre J, Alvarez MA. Immunocompetent truncated E2 glycoprotein of bovine viral diarrhea virus (BVDV) expressed in Nicotiana tabacum plants: a candidate antigen for new generation of veterinary vaccines. Vaccine 30(30), 4499-4504 (2012).
34. Wigdorovitz A, Carrillo C, Dus Santos MJ et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 255(2), 347-353 (1999).
35. Berinstein A, Vazquez-Rovere C, Asurmendi S et al. Mucosal and systemic immunization elicited by Newcastle disease virus (NDV) transgenic plants as antigens. Vaccine 23(48-49), 5583-5589 (2005).
36. Clemente M, Curilovic R, Sassone A, Zelada A, Angel SO, Mentaberry AN. Production of the main surface antigen of Toxoplasma gondii in tobacco leaves and analysis of its antigenicity and immunogenicity. Molecular biotechnology 30(1), 41-50 (2005).
37. Ferraro G, Becher ML, Angel SO, Zelada A, Mentaberry AN, Clemente M. Efficient expression of a Toxoplasma gondii dense granule Gra4 antigen in tobacco leaves. Experimental parasitology 120(1), 118-122 (2008).
38. Gomez E, Zoth SC, Asurmendi S, Vazquez Rovere C, Berinstein A. Expression of hemagglutinin-neuraminidase glycoprotein of newcastle disease Virus in agroinfiltrated Nicotiana benthamiana plants. Journal of biotechnology 144(4), 337-340 (2009).
39. Rybicki EP. Agricultural molecular biotechnology in South Africa: new developments from an old industry. Agricultural molecular biotechnology in South Africa: new developments from an old industry 2013(30/1/13)(1999)
40. Rybicki EP, Williamson AL, Meyers A, Hitzeroth, Ii. Vaccine farming in Cape Town. Human vaccines 7(3)(2011).
41. Sainsbury F, Lomonossoff GP. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant physiology 148(3), 1212-1218 (2008).
42. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Archives of virology 148(9), 1771-1786 (2003).
43. Giorgi C, Franconi R, Rybicki EP. Human papillomavirus vaccines in plants. Expert Review of Vaccines 9(8), 913-924 (2010).
44. Kane MA. Preventing cancer with vaccines: progress in the global control of cancer. Cancer prevention research 5(1), 24-29 (2012).
45. Mortimer E, Maclean JM, Mbewana S et al. Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC biotechnology 12, 14 (2012).
46. Landry N, Ward BJ, Trepanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PloS one 5(12), e15559 (2010).
47. Mutepfa DL. Expression of rotavirus capsid proteins in N. benthamiana leaves using an agrobacterium-mediated transient expression system. Expression of rotavirus capsid proteins in N. benthamiana leaves using an agrobacterium-mediated transient expression system. Master of Science, 97 (2011).
48. Zhou H, Guo L, Wang M et al. Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virology journal 8, 3 (2011).
49. Seheri LM, Page NA, Mawela MP, Mphahlele MJ, Steele AD. Rotavirus vaccination within the South African Expanded Programme on Immunisation. Vaccine 30 Suppl 3, C14-20 (2012).
50. Phiri KB. Agro-infiltration mediated expression of FMDV SAT-1 and SAT-2 P1 epitopes from Botswana isolates as surface presented antigens in TMV coat protein fusions. Agro-infiltration mediated expression of FMDV SAT-1 and SAT-2 P1 epitopes from Botswana isolates as surface presented antigens in TMV coat protein fusions Master of Science, 97 (2011).
51. Williamson A-L, Rybicki EP, Maclean JM, Becker-Hitzeroth II. Expression of viral proteins in plants. Expression of viral proteins in plants. WO 2006/119516(WO 2006/119516)(2006).
52. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clinical microbiology reviews 20(3), 489-510, table of contents (2007).
53. Musiychuk K, Stephenson N, Bi H et al. A launch vector for the production of vaccine antigens in plants. Influenza and other respiratory viruses 1(1), 19-25 (2007).